Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes. Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes.
BG Medicine (OTCMKTS:BGMD - Get Free Report) and Progyny (NASDAQ: PGNY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares BG Medicine and
Progyny (NASDAQ: PGNY - Get Free Report) and iSpecimen (NASDAQ: ISPC - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations. Profitability This table compares Progyny and iSpecimen's net margins,
ArrowMark Colorado Holdings LLC boosted its position in Progyny, Inc. (NASDAQ: PGNY) by 2.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,931,249 shares of the company's stock after purchasing an additional 39,666 shares during the quarter. ArrowMark Colorado
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook.
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum.
Progyny (PGNY) is undervalued at 9.3x forward P/E, with strong cash flow, expanding margins, and a resilient business model post-Amazon client loss. Headline FY26 growth appears muted (5.1%–9%) due to tough comps, but underlying growth excluding Amazon is 9.3–13.3%, with stable utilization rates near 1% and covered lives still expanding. PGNY's differentiated, outcome-focused platform, high retention, and buybacks (~15% share reduction in two years) support a robust medium-term investment case.
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.42 per share a year ago.
